an experimental cancer drug that works after a single round of treatment appears to be the most effective medicine yet for a rare form of leukemia, according to a study. scripps recently made an agreement with johnson &amp johnson's ortho pharmaceuticals to produce and distribute the drug once it's approved by the u.s. food and drug administration. however, interferon is less effective, and both of those treatments produce serious side effects. by contrast, the only unwanted effect of 2-cda was a few days of fever. by contrast, the only unwanted effect of 2-cda was a few days of fever. patients experienced no nausea, hair loss, rashes or other symptoms typical of cancer therapy. also unlike other treatments, this one appears to work after a single seven-day course of therapy. 